Neuropathic Therapy Center
Loma Linda, California, 92354-0200, United States
Location contact
Kyan Sahba, PhD
PRINCIPAL_INVESTIGATOR
Kyan Z Sahba, PhD
CONTACT
Mark Bussell, DPT
CONTACT
NCT Number: NCT07213843
The purpose of this study is to evaluate the effectiveness of three different interventions in improving neuropathy symptoms in individuals aged 35-85 with moderate to severe neuropathy. The study will compare three treatment groups: Intraneural Facilitation® (INF®) therapy alone, INF® therapy combined with Neuro vascular index (NVI) food-guided elimination (NVIf), and NVIf alone. The aim is to determine which treatment results in the greatest improvement in neuropathy symptoms, including quality of life, sensory and pain improvements, and functional outcomes.
Trial opening soon.
Get Notified35 year–85 year
All sexes
Interventional
Not applicable
Loma Linda, California, 92354-0200, United States
Kyan Sahba, PhD
PRINCIPAL_INVESTIGATOR
Kyan Z Sahba, PhD
CONTACT
Mark Bussell, DPT
CONTACT
The purpose of this investigator-initiated study is to observe the effectiveness of a manual physical therapy technique known as Intraneural Facilitation (INF®), both independently and in combination with a Nutritional Vascular Inflammation focused (NVIf) dietary intervention, in improving neurovascular function, pain, and physical performance in individuals with moderate to severe peripheral neuropathy (PN). Subjects will be randomized into one of the three interventions arms: (1) INF® therapy alone, (2) NVIf intervention alone or (3) a combination of both. INF® is a manual therapy, while NVIf utilizes ultrasound guided food elimination. Outcomes include pain (Visual analog scale), sensory function (Semmes Weinstein Monofilament), physical function (Lower extremity functional scale, 10-meter walk test, timed up and go) quality of life (Norfolk Quality of life-Diabetic neuropathy), and neurovascular blood flow analysis. Study participants will be 35-85 years old with a physician-confirmed diagnosis of moderate to severe lower extremity peripheral neuropathy and at least one symptom: numbness, tingling, burning, sharp pain, or increased sensitivity. They must score 0-60 on the Lower Extremity Functional Scale (LEFS), speak and understand English, provide written informed consent, and be willing to complete all study procedures, including intervention and follow-up visits. Participants must be able to ambulate independently with or without an assistive device. Subjects will be recruited using email and flyer through the Neuropathic Therapy Center (NTC) research interest list and through providers at Loma Linda's University (LLU) Health offices. 60 subjects will be recruited, and consent will take place at the LLU or at the Murrieta study site prior to randomization, administered by trained study staff authorized to obtain informed consent.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
INF® therapy is a manual technique designed to improve neural circulation by using a series of manual holds administered by a trained practitioner,
Other names: Intranerual Facilitation
NVIf is a dietary intervention that uses a patented ultrasound technology to assess vascular responses to food allergens
Other names: Neuro vascular index food-guided elimination
Time frame: Baseline (Week 0) and post-intervention (Week 4-5)
Pain intensity will be assessed using the Visual Analog Scale. Improvement will be indicated by reduced VAS scores. Unit of Measure: Millimeters on a 0-100 mm scale.
Time frame: Baseline (Week 0), mid-treatment (Week 3), and post-intervention (Week 4-5)
Sensory function will be assessed using the Semmes-Weinstein Monofilament test. Improvement will be indicated by increased monofilament detection. Detection threshold in grams (monofilament response: detected/not detected)
Time frame: Baseline (Week 0) and post-intervention (Week 4-5)
Functional limitation related to neuropathy will be assessed using the Lower Extremity Functional Scale. Improvement will be indicated by higher Lower Extremity Functional Scale scores. Scale score (0-80).
Time frame: Baseline (Week 0), mid-treatment (Week 3), and post-intervention (Week 4-5)
Gait speed will be assessed using the 10-Meter Walk Test. Improvement will be indicated by faster walk time. Seconds to complete 10 meters (converted to meters/second if applicable)
Time frame: Baseline (Week 0), mid-treatment (Week 3), and post-intervention (Week 4-5)
Mobility and fall risk will be assessed using the Timed Up and Go (TUG) test. Improvement will be indicated by shorter completion times. Unit of Measure: Seconds.
Time frame: Baseline (Week 0) and post-intervention (Week 4-5)
Quality of life will be measured using the Norfolk Quality of Life-Diabetic Neuropathy questionnaire to determine the effect of each treatment approach on overall patient well-being. Higher scores indicate greater impairment; a reduction reflects improved quality of life. Lowest score=0, means best quality of life with little to no neuropathy impacts. A maximum score of 138, means worst quality of life with severe impairments.
Time frame: Baseline (Week 0) and post-intervention (Week 4-5)
Mechanistic analysis will be performed using the Neurovascular Index with Philips Affinity 50 Ultrasound to evaluate changes in microvascular resistance and neurovascular blood flow, as well as the effect of NVI-guided food elimination on reducing neurovascular inflammation.
Contact information is provided by the study sponsor or research team.
Kyan Sahba, Post Doctoral Fellow, PhD
CONTACT
Mark Bussell, Clinical Director, DPT
CONTACT
Loma Linda University
Other
Combined Circulatory and Dietary Interventions for Neuropathy (CDIN)
Acronym: CDIN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07730567
Diabete Type 2, Diabetes Mellitus
Seoul, South Korea
View Trial DetailsNCT07713836
Body Weight, Diabete Type 2
Dallas, Texas, United States
View Trial DetailsNCT07563699
Diabete Type 2, Diabetes Mellitus
Tel Aviv, Israel
View Trial DetailsNCT07619677
Cardiovascular Diseases, Diabete Type 2
View Trial Details